Billy Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Billy Lu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Adam Siepel
Simons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
10 shared publications - Armin Scheben
Simons Center for Quantitative Biology Cold Spring Harbor Laboratory Cold Spring Harbor New York USA
10 shared publications - Caroline L. Buckholtz
Cooper University Healthcare, Camden, New Jersey
10 shared publications - Christopher E. Barbieri
Department of Urology, Weill Cornell Medicine, New York, USA
10 shared publications - Daniele Ramazzotti
Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
10 shared publications - Dawid G. Nowak
Weill Cornell Medicine
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S6-S13 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S6. Barcode design and analysis. Supplementary Figure S7. Analysis and simulation barcode data to evaluate EvoTraceR performance. Supplementary Figure S8. Pipeline for detecting and calling edits in barcode. Supplementary Figure S9. Temporal accumulation of barcode edits in vivo. Supplementary Figure S10. Eco-statistical analysis of MMUS1495. Supplementary Figure S11. Metastatic trajectories for EvoCaP mouse cohorts. Supplementary Figure S12. Organ diversity between EvoCaP mice. Supplementary Figure S13. Expansion of EvoCaP platform in vitro.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S6-S13 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S6. Barcode design and analysis. Supplementary Figure S7. Analysis and simulation barcode data to evaluate EvoTraceR performance. Supplementary Figure S8. Pipeline for detecting and calling edits in barcode. Supplementary Figure S9. Temporal accumulation of barcode edits in vivo. Supplementary Figure S10. Eco-statistical analysis of MMUS1495. Supplementary Figure S11. Metastatic trajectories for EvoCaP mouse cohorts. Supplementary Figure S12. Organ diversity between EvoCaP mice. Supplementary Figure S13. Expansion of EvoCaP platform in vitro.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Table S1. Bootstrap-based 95% confidence bounds for MMUS1469 migration counts and seeding topologies for all clonal populations (CPs). Supplementary Table S2. Bootstrap-based 95% confidence bounds for MMUS1495 migration counts and seeding topologies for all clonal populations (CPs).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Table S1. Bootstrap-based 95% confidence bounds for MMUS1469 migration counts and seeding topologies for all clonal populations (CPs). Supplementary Table S2. Bootstrap-based 95% confidence bounds for MMUS1495 migration counts and seeding topologies for all clonal populations (CPs).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S5. Immunostaining of tissues excised from prostate tumor regions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S5. Immunostaining of tissues excised from prostate tumor regions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site.Significance:Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site.Significance:Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).
- Open Access
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Table S1. Bootstrap-based 95% confidence bounds for MMUS1469 migration counts and seeding topologies for all clonal populations (CPs). Supplementary Table S2. Bootstrap-based 95% confidence bounds for MMUS1495 migration counts and seeding topologies for all clonal populations (CPs).
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Table S1. Bootstrap-based 95% confidence bounds for MMUS1469 migration counts and seeding topologies for all clonal populations (CPs). Supplementary Table S2. Bootstrap-based 95% confidence bounds for MMUS1495 migration counts and seeding topologies for all clonal populations (CPs).
- Open Access
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S6-S13 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S6. Barcode design and analysis. Supplementary Figure S7. Analysis and simulation barcode data to evaluate EvoTraceR performance. Supplementary Figure S8. Pipeline for detecting and calling edits in barcode. Supplementary Figure S9. Temporal accumulation of barcode edits in vivo. Supplementary Figure S10. Eco-statistical analysis of MMUS1495. Supplementary Figure S11. Metastatic trajectories for EvoCaP mouse cohorts. Supplementary Figure S12. Organ diversity between EvoCaP mice. Supplementary Figure S13. Expansion of EvoCaP platform in vitro.
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S6-S13 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S6. Barcode design and analysis. Supplementary Figure S7. Analysis and simulation barcode data to evaluate EvoTraceR performance. Supplementary Figure S8. Pipeline for detecting and calling edits in barcode. Supplementary Figure S9. Temporal accumulation of barcode edits in vivo. Supplementary Figure S10. Eco-statistical analysis of MMUS1495. Supplementary Figure S11. Metastatic trajectories for EvoCaP mouse cohorts. Supplementary Figure S12. Organ diversity between EvoCaP mice. Supplementary Figure S13. Expansion of EvoCaP platform in vitro.
- Open Access
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S5. Immunostaining of tissues excised from prostate tumor regions.
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S5. Immunostaining of tissues excised from prostate tumor regions.
- Open Access
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.
- 4 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.
- 5 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (10) , 1990-2009
Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).
- 5 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (10) , 1990-2009
Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).